Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

ompetition, and others stated in risk factors contained in our SEC filings.  We cannot assure that we have identified all risks or that others may emerge which we do not anticipate.  You should not place undue reliance on forward-looking statements.  Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Galectin Therapeutics and its associated logo is a trademark of Galectin Therapeutics Inc.

 Condensed Consolidated Statements of OperationsThree Months
EndedDecember 31,Twelve MonthsEndedDecember 31,2012201120122011(in thousands, except per share data)

(unaudited)Operating expenses:  Research and development

$1,002

$862

$4,527

$3,552  General and administrative

1,380

2,510

5,372

6,857  Total operating expenses

2,382

3,372

9,899

10,409Total operating loss

(2,382)

(3,372)

(9,899)

(10,409)Other income and (expense):  Interest income

6

4

24

18  Change in fair value of warrant liabilities

-

-

-

(524)  Other income

-

-

200

-Total other income (expense)

6

4

224

(506)Net loss

$(2,376)

$(3,368)

$(9,675)

$(10,915)Preferred stock dividends and accretion costs

(332)

(350)

(1,206)

(1,798)Net loss applicable to common stock

$(2,708)

$(3,718)

$(10,881)

$(12,713)Basic and diluted net loss per share

$  (0.17)

$  (0.29)

$  (0.72)

$  (1.06)Shares used in computing basic and diluted net loss per share

15,966

12,846

15,131

11,986 Condensed Consolidated Balance She
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... CA (PRWEB) October 30, 2014 ... today that they have manually curated public data source ... non profit customers. the data is now available ... curates and unifies public and internal data sources for ... and knowledge out of the data that becomes more ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Spartan Bioscience ... Spartan RX CYP2C19 System . It detects CYP2C19 genetic ... cheek swab. , The Spartan RX CYP2C19 System is ... has been approved in Canada. Due to the system’s ... may be used by healthcare professionals such as doctors, ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success and ... its fleet of high volume High Pressure Processing (HPP) systems. ... return to PackExpo this year, which is where we first ... Jeff Williams, CEO at Avure. “Sales of the new Avure ... meeting the challenges of market demand for higher throughput. We ...
(Date:10/30/2014)... 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... will present a company overview at the Nomura Biotechnology Conference ... Boston, MA. A live ... & Media" section of the Company,s website, www.isispharm.com .  ... 48 hours and will be archived for a limited time. ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... BRUNSWICK, N.J. and NANJING, China, Sept. 3 ,Acesys ... combining the drug discovery expertise and project management,capabilities ... chemistry resources and,favorable cost structure of Acesys in ... alliance will encompass all,aspects of medicinal chemistry for ...
... strategic planner for an organization in the filter industry? ... Are you part of a filter company looking ... the growth segments in the filter and filtration markets. ... Place in Charlotte, NC, the American Filtration and Separations ...
... HOBOKEN, N.J. - Dr. Yong Shi of Stevens ... grant for his project titled "MEMS Umbrella-Shaped Actuator ... was approved on scientific/technical merit for three years ... the research is to design, fabricate and test ...
Cached Biology Technology:Acesys and Provid Announce Alliance for Medicinal Chemistry Services 2Filter Markets - Discover the Growth Segments 2Filter Markets - Discover the Growth Segments 3Dr. Yong Shi awarded NSF grant 2
(Date:10/31/2014)... Bugnyar and his team have been studying the ... Northern Austrian Alps for years. They observed that ... as grooming and playing. However, they also observed ... a third individual. Although in about 50 % ... broke up the two affiliating ravens, intervening can ...
(Date:10/30/2014)... When most animals begin life, cells immediately begin accepting ... organ. However, mammals, including humans, are special. The cells ... choice – to become the protective placenta or to ... critical first step that research from Michigan State University ... current issue of PLOS Genetics , ...
(Date:10/30/2014)... developed a suite of technologies that can be used ... applications in everything from search and rescue to service ... platform for computer-mediated communication between humans and dogs that ... behavioral signals and sending them clear and unambiguous cues ... of computer science at NC State and co-lead author ...
Breaking Biology News(10 mins):Identifying the source of stem cells 2New tech aims to improve communication between dogs and humans 2
... release is available in Spanish . ... However, human nutrition researchers agree that many questions remain about ... Studies led by Agricultural Research Service (ARS) molecular biologist Daniel ... Certain kinds of inflammation can increase risk of cancer ...
... is available in Spanish . Researchers ... the Clinical Hospital San Cecilio and the University Rey Juan ... patients with tension headache improves within 24 hours after receiving ... an increasing incidence in the population. This type of disorder ...
... The ,Geographic Chemicals in Groundwaters and Soils, event ... Marie Curie Research Training Network. This network, coordinated ... to highlight the environmental effect including the effect ... in groundwater and soils. Held today and tomorrow ...
Cached Biology News:Luteolin stars in study of healthful plant compounds 2University of Manchester academics at international conference on geographic chemicals 2
...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
... are macroporous polystyrene beads for hydrophobic interaction ... for adsorbing organics of molecular weight less ... are useful for the adsorption of nonpolar ... the removal of detergents such as Triton ...
... Immunogen : Fusion protein corresponding ... of human Mi-2 Formulation: 0.7M ... 0.035% sodium azide, containing 30% ... by immunoblot on Hela nuclear ...
Biology Products: